Counterproductive effects of Daratumumab and checkpoint inhibitor for the treatment of patients with relapsing NK/T lymphoma
Lee, W.; Jinquan, L.; Tang, T. P.; Tan, D.; Kia Joo, P.; Kim Peng, T.; Liangwei, W.; Ser Mei, K.; Choon Kiat, O.; Rotzschke, O.
Show abstract
Natural killer/T cell lymphoma (NK/T L) is an aggressive malignancy associated with poor prognosis in relapsed patients. Although L-asparaginase based treatments are recommended as first-line treatment in relapsed patients, advances in immunotherapies such as checkpoint inhibitions have provided new therapeutic alternatives. However, as clinical outcomes for checkpoint inhibitors seemed to vary between NK/T L patients, combination therapies have been suggested to improve treatment efficacy. Here, we compared the effects of Daratumumab (anti-CD38)/anti-PD-1 combination therapy versus anti-PD-1 monotherapy on two relapsed NK/T L patients. Anti-PD-1 triggered an upregulation of CD38 on activated T cells, leading to depletion by Daratumumab. Concomittantly, EBV-specific antibody titer was also reduced alongside with depletion of CD38+ B cells and antibody-producing plasmablasts. Taken together, combining anti-CD38 and anti-PD-1 is likely to be antithetic.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Circulating Low Density Neutrophils Are Associated with Resistance to First-Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer 93%
- Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting 92%
- Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumor necrosis factor signaling pathways 92%
Similar papers in this journal
- CD20 expression regulates CD37 levels in B-cell lymphoma: implications for immunotherapies. 93%
- CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma 92%
- Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden 91%
Similar papers in this journal
- A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia 94%
- Excess BAFF Alters NR4As Expression Levels and Breg Function of Human Precursor-like Marginal Zone B-cells in the Context of HIV-1 infection 92%
- Analysis Of Immune Escape Variants From Antibody-Based Therapeutics Against COVID-19 91%
Similar papers in this journal
- Upregulation of Activation Induced Cell Markers (AIM) among Severe COVID-19 patients in Bangladesh 93%
- Long-term T cell perturbations and waning antibody levels in individuals needing hospitalization for COVID-19 92%
- Antigenic determinants of SARS-CoV-2-specific CD4 + T cell lines reveals M protein-driven dysregulation of interferon signaling 92%
Similar papers in this journal
- The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment 93%
- Characterization and establishment of a novel EBV strain simultaneously associated with nasopharyngeal carcinoma and B-cell lymphoma 92%
- Establishment of primary renal lymphoma model and the clinical relevance 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.